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Abstract
Human xylazine use in Puerto Rico merits particular attention for its unprecedented scale and depth. Although
Puerto Rican injecting drug users (IDUs) have reported using this drug since the early 2000s, little is being done in
the research and service delivery sectors as it is claimed that xylazine severely impacts the health of its users. This
report provides information on xylazine use and its associated harms. Data from one semi-structured interview
collected in New York City (2007-2008) as part of a larger research study with migrant Puerto Rican drug users is
presented as a case study. Xylazine, a veterinary sedative, is an adulterant and complement to other drugs and its
chronic use is reported to be associated with physical deterioration. Because human xylazine use has been
reported in other locations outside of Puerto Rico, this substance could also emerge as an adulterant in other
markets to the levels currently experienced in Puerto Rico. Research and interventions are needed to provide
adequate services on the island, better understand how the use of xylazine affects its users, and to reduce the
possibility of increased xylazine use on the state-side.
Findings
Since the early 2000’sP u e r t oR i c oh a ss e e na ne m e r -
gence of a substance among its injecting drug users
(IDUs) called xylazine. Xylazine is a non-opiate sedative,
analgesic, and muscle relaxant certified exclusively for
veterinary use. The harms associated with the chronic
use of xylazine, or “Anestesia de Caballo“ (Horse Anes-
thetic) as it is commonly known on the streets of Puerto
Rico, are not well documented as it has received little
attention from researchers. Yet, some associations have
been made between the use of xylazine and open skin
ulcers [1] that have serious negative effects on the daily
lives of injecting drug users. While the precise reasons
why xylazine emerged in the island’sd r u gm a r k e ta r e
still unknown, it is argued that the same motivating fac-
tors could also occur in other markets, including those
in the continental United States and create an equally
problematic public health issue.
Having worked in the field of drug use for many years
as a direct service provider and as a researcher, this
author directly witnessed many of the harms associated
with xylazine use. This short report is framed by those
service provision experiences on both the island and the
state-side as well as by this researcher’s studies in injec-
tion drug use. The goal of this report is to present
information on human xylazine use and its associated
harms. In turn, this information highlights the need to
generate additional research and adequate services to
reduce these drug-related harms. Illustrations of how
xylazine is viewed from a drug user’s perspective are
presented in data from an interview conducted for a lar-
ger study. The specific interview was chosen out of a
small number that discussed xylazine use in Puerto
Rico because of the participant’s extensive experience
with the substance and his detailed and comprehensive
description of these experiences. Xylazine use was not a
main topic in the interview protocol, therefore the topic
was only discussed by some research participants. The
lager study was the author’s dissertation research (UMI
No. 3396474) and data was collected between 2007 and
2008 with Puerto Rican injecting drug users who
relocated from Puerto Rico to New York City for drug
treatment services. Human subjects approval was
attained from the City University of New York’sG r a d u -
ate Center IRB. A first wave of anonymous ethno-
graphic data was collected through participant
observation. Informed by the contacts and knowledge
afforded by the participant observation, a second wave
of data was collected utilizing semi-structured inter-
views (N = 13) for which all participants signed consent
forms and were audio recorded. Confidentiality was
further assured to participants by securing an NIH-
issued Certificate of Confidentiality.
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exists [2-6], there is a dearth of research on how this
substance becomes diverted to the illicit drug market,
the context of use, and the harms related to its chronic
use. One study [7] detected xylazine and fentanyl (the
former being an veterinary sedative/anesthetic and the
latter a synthetic opiate used for the medical treatment
of pain in humans) in drug related deaths in Philadel-
phia, Pennsylvania and suggested that both drugs could
be used as adulterants in heroin. While the precise rea-
sons why these drugs are used as adulterants are
unknown, the authors mentioned that “financial con-
cerns, e.g., increased street sale value, and enhanced
drug effects may be some of the driving forces” (p.497).
More importantly, they advocate for research on xyla-
zine and its effect on humans because: “it is a veterinary
drug and is not approved for human use. [...] Unfortu-
nately, its use in humans can be fatal, especially in over-
dose cases.” (p.498)
Xylazine was confirmed as the anesthetic substance
used in Puerto Rico by testing exchanged needles in 29
sites in 11 municipalities [1]. The authors of the study,
beyond asserting that the substance was not “confined
to a small area in Puerto Rico” (p. 292) mentioned that
xylazine was highly prevalent in syringes collected in
cattle-farming towns (e.g., Arecibo, Yauco, and Gua-
nica: 98%, 100%, and 100% respectively). Noteworthy is
that “IDUs whose syringes contained Xyz were also
more likely to complain of poor health than those
whose syringes did not, [...] [t]he former also had
higher incidence of skin ulcers than the latter” (p.292).
Interestingly, their data did not point to homelessness
as having a significant impact on skin ulcers. Research
such as this is critical as it begins to tease apart the
negative effects of the substance itself from those
effects of the contextual factors that condition the use
of xylazine. The study also stressed some points where
xylazine-related information is needed: 1) its distribu-
tion, 2) its chronic use and its association to physical
deterioration, and 3) how widespread xylazine abuse is
beyond the island.
Similarly, and unpublished study by Reyes JC, Robles
R, Negrón J, Colón H, Matos TD, and Calderón JM
titled The Emerging of Xylazine as a New Drug of Abuse
and its Health Consequences Among Drug Users in
Puerto Rico found a prevalence of xylazine use in prior
30-days of 80.7% among its sample of 89 drug users
recruited from 12 communities from the San Juan
metropolitan area. Xylazine users were more likely to be
male, under the age of 30, living in a rural area, and
injecting versus inhaling xylazine. Additionally, 35.2%
reported skin lesions, 28.2% reported an increase in
injection use, and 21.1% reported at least one overdose
episode.
Xylazine as an adulterant and complement to other
drugs: Distribution
Pipo (pseudonym), a savvy consumer, describes how he
first encountered xylazine and how it was marketed in
Puerto Rico; first as an adulterant to heroin packaged
for the consumer to control the ratio him or herself and
later in pre-mixed form.
I opened up the bag and when I threw it in the coo-
ker, a really fucking strong medicine smell. [...] That
was the first heroin that they cut with anestesia
(xylazine) in Puerto Rico, the “Blue Demon”. [...]
What those people did was that they would place
heroin inside, they would then fold the paper the
first time, the first fold, there outside they would put
the anestesia and then the fold. They would call
that, el regalito (the small gift). And when you
would open the bag, you would open the first fold
and there was a half a bag [...] [of] anestesia and you
would put some. And when you would open [the
rest of] the bag you would put the other [heroin].
[...] It was later when they started to mix it, [...] 80%
anestesia and 20% heroin.
Pipo indicated that xylazine is marketed in the same
locations as heroin and it has been sold in packages
together, but not mixed, with heroin as well as in pre-
mixed form. Non-mixed packages allow users to control
the heroin/xylazine ratio - and therefore controlling
some of the substances’ effects on the user.
Another non-mixed packaging form, presumably
adjusting to users’ demand who often seek a balance
between the “down” of both the heroin and xylazine,
added cocaine. This packaging form was called “el com-
bito“ (the small combo):
“They put coke, a $3 of coke. They put a $3 of her-
oin. And an anestesia [xylazine] of $2. You know,
heroin [and] the anestesia are pure.”
In essence, el combito is a speedball - a mix or heroin
and cocaine - with xylazine package for $8 with each sub-
stance kept separate for the user to tailor to her/his liking.
Where xylazine and heroin are sold pre-mixed, adul-
terating the heroin with xylazine becomes a sought after
skill as it involves taking xylazine in its original liquid
form and mixing it with heroin without damaging either
substance. This was reported to be done locally so it
could be packaged and sold as soon as the mixture was
ready.
Chronic use and physical deterioration
Two key issues about the chronic use of xylazine are the
physical dependence to the substance and the noticeable
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by describing the first time he used xylazine and his
later physical dependence on both heroin and xylazine
along with his need to avoid withdrawal symptoms:
Is h o tt h eanestesia [...] and I felt asleep face first
and when I opened my eyes five hours had gone by
and I was laying on the floor. [...] I don’t remember
anything. I don’t remember anything! I fell down
and I was gone. And I said: What the hell is this?!
Oh, and I woke up sick [withdrawing]!
[...]
I get there and don’t cop just heroin. I cop anestesia.
Because that it what is going to get me high and
what is going to get me straight [and reverse with-
drawal symptoms]. I am not going to waste my
m o n e yi nj u s th e r o i nb e c a u s eI ’m going to stay the
same. Do you understand? I’m going to stay the
same.
Pre-mixed with heroin or not, xylazine users claim
that chronic use of this substance creates open skin
ulcers. Yet, the author only found one published study
[1] and one unpublished poster presentation that
explored this important association between xylazine
and skin ulcers. Among the drug using community,
these open ulcers are referred to as abscesses.
[T]he times when the abscesses [...] started to
appear, I would come here, to the United States. [...]
[When the abscesses began to appear] I already
knew. [...] I had seen them [before]. [...] [T]here are
people that take a longer time in blowing up [with
abscesses] than others. [...] I am one in which it took
a while. But when I saw that people were rotting I
would get scared because I always have said that I
am a junky with style.
These ulcers are a serious health concern for drug
users for several key reasons. First, they are painful. This
promotes further injections in the injection/ulcer site
with xylazine (functioning as a sedative/anesthetic). This
subsequently creates a cycle that heightens the need for
medical attention and adequate treatment. It should be
noted, however, that not all ulcers appear in the injec-
tion sites, they are also reported to appear in non-injec-
tion site extremities. Second, these open skin ulcers
emit a strong odor, ooze, and in severe cases limit the
mobility of the extremities. In some cases, amputations
have been performed on the affected extremity/extremi-
ties. Third, xylazine users attest that when they have
asked for help from clinics on the island, health profes-
sionals commonly deny services because of their ulcers.
Pipo, in the above interview mentions that he was lucky
because the ulcers took time to develop in his body - by
the time they developed, he had relocated to the state-
side and could access medical services. He points to the
lack of treatment for these ulcers in Puerto Rico, the
lack of xylazine availability on the state-side, and the
knowledge that some state-side hospitals have gained by
providing services to drug users that are relocated from
Puerto Rico to the state-side for treatment by the local
Puerto Rican government.
With no specialized treatment services for xylazine
users on the island, except for some community based
organizations who attend to xylazine user’s basic health-
care needs (e.g., medical/wound care, syringe exchange,
education), these open ulcers grow to emit a strong
odor and look severe to both the medically trained and
the un-trained eye. The combination of the “basic”
stigma towards drug users [8] compounded with the
olfactory and visual severity of these open skin ulcers
(re)stigmatize and further socially exclude these drug
users. A colleague said it best when she saw the ulcers
and the effects these had on non-users in the island:
“injecting drug users are being treated as if they were
lepers.”
The spread of xylazine
Because human xylazine use has been reported in other
locations and not just in Puerto Rico (e.g., Philadelphia)
it stands that this substance could also emerge as an
adulterant in other markets to the levels currently
experienced in Puerto Rico. Surely, the scarcity of treat-
ment services for drug users on the island in compari-
son to the state-side [9] and the current trend of local
elected official in Puerto Rico relocating IDU to the
state-side for drug treatment services does not aid to
contain this situation to the island. Yet, ignoring the
emergence of a substance like xylazine will not result in
sound public health responses and will only add to
the detriment of drug users and society as a whole. Spe-
cialized services and research need to be dedicated to
xylazine users - and Puerto Rican IDUs in general.
Meanwhile, tracking the use of xylazine on the state-
side markets (without negatively drug-profiling Puerto
Rican communities) seems like a pertinent first step, as
xylazine is an already known adulterant, albeit only in
Puerto Rico has it been used to these alarming levels.
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